Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Brain Tumor | Research

Histological types of brain tumors diagnosed at the Kenyatta National Hospital between 2016 and 2019: a retrospective study

Authors: Samwel Rema Gesaka, Parmenas Minda Okemwa, Philip Maseghe Mwachaka

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Purpose

To determine the histological types of brain tumors diagnosed at the Kenyatta National Hospital, Nairobi, Kenya.

Methods

This retrospective study retrieved patient-archived records at the Kenyatta National Hospital for the period 2016–2019. The histological types of brain tumors were assessed according to age, sex, and the WHO classification for CNS tumors using the GNU PSPP version 1.6.2-g78a33 software. Results were presented in tables and figures.

Results

During the study period, brain tumors appeared to increase gradually; however, there was a decline in 2018. During the study period, 345 brain tumor records were retrieved. Data on age were missing 33 records; hence, 312 records were included for age analyses. The mean age for the pediatrics and adults was 9 (± 5 SD) and 45 (± 14 SD) years, respectively. 88 (28.2%) and 224 (71.8%) tumors were diagnosed among pediatrics and adults, respectively. Most tumors, 60 (19.2%) were reported in patients aged ≤ 10 years, followed by 55 (17.6%), 48 (15.4%), and 47 (15.1%) in patients aged 31–40, 51–60, and 41–50, years, respectively. In both pediatrics and adults, most tumors were diagnosed in females aged ≤ 10 years and 31–40 years, respectively. Overall, two peaks were observed in patients aged 5–15 years and 40–45 years. Gliomas, 43 (48.9%) and medulloblastomas, 21 (23.9%) were the most common tumors in pediatrics, whereas meningiomas, 107 (47.8%) and gliomas, 70 (31.3%) were the most common tumors in adults. Most pediatric and adult tumors were benign with 50 (56.8%) and 157 (70.1%) cases, respectively. Low-grade gliomas and medulloblastomas were the commonest benign and malignant tumors among pediatrics, with 31 (62%) and 21 (55.3%) cases, respectively. Conversely, meningiomas and high-grade gliomas were the most common benign and malignant tumors in adults, with 106 (67.5%) and 44 (65.7%) cases, respectively.

Conclusion

This study highlights the existing burden of brain tumors in Kenya and data from KNH may be representative of the national burden of BTs. This study lays a foundation for subsequent clinical and epidemiological studies and emphasizes the need to adopt existing reporting standards to help realize a complete picture of the burden of brain tumors in Kenya.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Stewart B. 2014. Wild International Agency for Research on Cancer. In: WHO CP (Ed). World Cancer Report. International Agency for Research on Cancer: Lyon.
3.
Bell JS, Koffie RM, Rattani A, Dewan MC, Baticulon RE, Qureshi MM, et al. Global incidence of brain and spinal tumors by geographic region and income level based on cancer registry data. J Clin Neurosci. 2019;66:121–7.PubMedCrossRef
4.
World Health Organization. 2020. Kenya Source: Globocan 2020.
5.
Uwishema O, Frederiksen KS, Badri R, Pradhan AU, Shariff S, Adanur I, et al. Epidemiology and etiology of brain cancer in Africa: A systematic review. Brain Behav. 2023;13(9):e3112.PubMedPubMedCentralCrossRef
6.
Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of brain and other CNS tumors current neurology and neuroscience Reports, vol. 21. Berlin: Springer; 2021.
7.
Hazmiri FE, Boukis F, Benali SA, El Ganouni NCI, Rais H. Brain tumors in children: about 136 cases. Pan African Med J. 2018;30:1–8.
8.
Ostrom QT, Fahmideh MA, Cote DJ, Muskens IS, Schraw JM, Scheurer ME, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019;21(11):1357–75.PubMedPubMedCentralCrossRef
9.
McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34(981):98.
10.
Jemal A, Torre L, Street W, Bray F. The cancer atlas. Am Cancer Soc. 2019;1–69.
11.
Živković N, Mihailović G, Marković M, Berisavac I, Spaić M. Epidemiological features of brain tumors. Srp Arh Celok Lek. 2014;141(11–12):823–9.
12.
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21:V1-100.PubMedPubMedCentralCrossRef
13.
14.
15.
Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21.PubMedPubMedCentralCrossRef
16.
Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016;1:24.CrossRef
17.
MbiFeh MKN, Lyon KA, Brahmaroutu AV, Tadipatri R, Fonkem E. The need for a central brain tumor registry in Africa: a review of central nervous system tumors in Africa from 1960 to 2017. Neurooncol Pract. 2021;8(3):337–44.
18.
Kanmounye US, Karekezi C, Nyalundja AD, Awad AK, Laeke T, Balogun JA. Adult brain tumors in Sub-Saharan Africa: a scoping review. Neuro Oncol. 2022;24(10):1799–806.PubMedPubMedCentralCrossRef
19.
Kamita M, Mweni S, Nzioka A, Figueroa JD, Makokha F. Analysis of cancer diagnoses from 2015–2019 within Machakos County, Kenya, support establishment of Cancer Centre in 2019 likely changing referral patterns. Wellcome Open Res. 2020;16(5):290.CrossRef
20.
Kamita M, Bird P, Akinyi B, Kamau RW, Carter R, Muma S, et al. Cancer referrals at African Inland Church Kijabe Hospital, Kiambu County (2014–2020) and the impact of COVID-19. Int Health. 2023;15(5):547–56.PubMedPubMedCentralCrossRef
21.
Keogh BP, Henson JW. Clinical manifestations and diagnostic imaging of brain tumors. Hematol Oncol Clin North Am. 2012;26(4):733–55.PubMedCrossRef
22.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.PubMedCrossRef
23.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.PubMedPubMedCentralCrossRef
24.
25.
26.
Uwishema O, Frederiksen KS, Badri R, Pradhan AU, Shariff S, Adanur I, et al. Epidemiology and etiology of brain cancer in Africa: a systematic review. Brain Behav. 2023;13(9):e3112.PubMedPubMedCentralCrossRef
27.
Aderinto N, AbdulBasitOpeyemi M, Opanike J, Afolayan O, Sakaiwa N. Navigating the challenges of neuro-oncology in Africa: addressing diagnostic and treatment barriers in the region: a correspondence. Int J Surg Global Health. 2023;6(3):e136–e136.CrossRef
28.
Patel AP, Fisher JL, Nichols E, Abd-Allah F, Abdela J, Abdelalim A, et al. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):376–93.CrossRef
29.
30.
31.
32.
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22:1–96.CrossRef
33.
Jibrin P, Ibebuike K, Ado-Wanka AN. Histo-pathological pattern of intracranial tumours in the national hospital. Abuja Afr Health Sci. 2018;18(2):281–6.PubMed
34.
Soyemi SS, Oyewole OO. Spectrum of intracranial tumours in a tertiary health care facility: our findings. Pan Afr Med J. 2015;20:1–5.CrossRef
35.
Mwang’ombe NJM, Ombachi RB. Brain tumours at the Kenyatta National Hospital Nairobi. East Afr Med J. 2000;77(8):444–7.PubMed
36.
37.
Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017;35(21):2370–7.PubMedCrossRef
38.
39.
Abalo KD, Rage E, Leuraud K, Richardson DB, Le Pointe HD, Laurier D, et al. Early life ionizing radiation exposure and cancer risks: systematic review and meta-analysis. Pediatr Radiol. 2021;51(1):45–56.PubMedCrossRef
40.
41.
Braganza MZ, Kitahara CM, Berrington De González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14(11):1316–24.PubMedPubMedCentralCrossRef
42.
Bailey HD, Rios P, Lacour B, Guerrini-Rousseau L, Bertozzi AI, Leblond P, et al. Factors related to pregnancy and birth and the risk of childhood brain tumours: the ESTELLE and ESCALE studies (SFCE, France). Int J Cancer. 2017;140(8):1757–69.PubMedCrossRef
43.
Muddegowda PH, Lingegowda JB, Kurpad RR, Srinivasan S, Manjunatha HK. Prevalence of primary CNS tumors in a diagnostic setup in Nairobi, Kenya. Indian J Pathol Oncol. 2018;5(4):631–5.CrossRef
44.
Ibebuike K, Ouma J, Gopal R. Meningiomas among intracranial neoplasms in Johannesburg, South Africa: prevalence, clinical observations and review of the literature. Afr Health Sci. 2013;13(1):118–21.PubMedPubMedCentral
45.
Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994;6(2):180–4.PubMedCrossRef
46.
Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9.PubMedPubMedCentral
47.
Custer B, Longstreth JT, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer. 2006;7:6.
48.
Amirian ES, Zhou R, Wrensch MR, Olson SH, Scheurer ME, Il’Yasova D, et al. Approaching a scientific consensus on the association between allergies and Glioma risk: a report from the Glioma international case-control study. Cancer Epidemiol Biomarkers Prev. 2016;25(2):282–90.PubMedPubMedCentralCrossRef
49.
Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’Yasova D, Kinnersley B, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017;49(5):789–94.PubMedPubMedCentralCrossRef
50.
Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. 2015;6(40):42468–77.PubMedPubMedCentralCrossRef
51.
Muskens IS, Hansen HM, Smirnov IV, Molinaro AM, Bondy ML, Schildkraut JM, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased meningioma risk. J Neurooncol. 2019;142(3):479–87.PubMedPubMedCentralCrossRef
52.
Carles C, Esquirol Y, Turuban M, Piel C, Migault L, Pouchieu C, et al. Residential proximity to power lines and risk of brain tumor in the general population. Environ Res. 2020;1:185.
53.
Turner MC, Benke G, Bowman JD, Figuerola J, Fleming S, Hours M, et al. Occupational exposure to extremely low-frequency magnetic fields and brain tumor risks in the INTEROCC study. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1863–72.PubMedPubMedCentralCrossRef
54.
Porter AB, Lachance DH, Johnson DR. Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes Control. 2015;26(2):179–85.PubMedCrossRef
55.
Cote DJ, Ostrom QT, Gittleman H, Duncan KR, CreveCoeur TS, Kruchko C, et al. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer. 2019;125(19):3390–400.PubMedCrossRef
56.
Anic GM, Madden MH, Nabors LB, Olson JJ, Larocca RV, Thompson ZJ, et al. Reproductive factors and risk of primary brain tumors in women. J Neurooncol. 2014;118(2):297–304.PubMedPubMedCentralCrossRef
57.
Bello-Alvarez C, Camacho-Arroyo I. Impact of sex in the prevalence and progression of glioblastomas: the role of gonadal steroid hormones. Biol Sex Differ. 2021;12(1):1–13.CrossRef
58.
Anic GM, Madden MH, Nabors LB, Olson JJ, Larocca RV, Thompson ZJ, et al. Reproductive factors and risk of primary brain tumors in women. J Neurooncol. 2014;118(2):297–304.PubMedPubMedCentralCrossRef
59.
Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A. Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control. 2010;21(12):2149–56.PubMedCrossRef
60.
61.
Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. Association of meningioma with reproductive factors. Int J Cancer. 2006;119(5):1152–7.PubMedCrossRef
Metadata
Title
Histological types of brain tumors diagnosed at the Kenyatta National Hospital between 2016 and 2019: a retrospective study
Authors
Samwel Rema Gesaka
Parmenas Minda Okemwa
Philip Maseghe Mwachaka
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00893-6

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue

Research

Development of chitosan-folate modified PLGA nanoparticles for targeted delivery of diosgenin as an anticancer agent

Research

A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer

Research

MiR-6839-5p inhibits cell proliferation, migration and invasion; a possible correlation with the suppressing VEGFA expression in human chondrosarcoma cells

Research

Elucidating the impact of parthanatos-related microRNAs on the tumoral immune microenvironment and clinical outcome in low-grade gliomas

Research

Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel

Review

The role of stromal cells in epithelial–mesenchymal plasticity and its therapeutic potential
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits